One of the biggest medical stories of 2023 was the surge in prescription medication for weight loss. Type 2 diabetes drugs were already being used off label for weight loss, but with the FDA's approval to use these medications to treat obesity, the demand skyrocketed.
Two big studies came out of Case Western Reserve University on the wildly popular weight loss drugs with glucagon-like peptide-1 (glp-1) receptor agonists.
The first found the drugs may reduce risk of colorectal cancer, in both people with diabetes and obesity.
The second, found semaglutide, that’s in Wegovy and Ozempic, had a significantly lower risk of suicidal thoughts compared to others.
Previously a Cleveland Clinic study found semaglutide, found in Wegovy and Ozemic, cut the risk of severe heart problems.
However, the FDA is looking into reports of adverse side effects that were self-reported. Some users claim some of these new drugs caused suicidal thoughts, hair loss and airway obstruction.
The most common side effects are nausea, constipation and pancreatitis.
3News' Monica Robins reports: [ Ссылка ]
